Malaria remains a leading cause of morbidity and mortality in the modern world, with 247 million cases and 619,000 deaths in 2021. The past century has seen many advances in the treatment and prevention of malaria, and the progress made thus far cannot be discounted. Despite these advances, the World Health Organization reports that progress in the reduction of cases and deaths due to malaria has plateaued since 2019. A significant challenge in the treatment and prevention of malaria is the ability of Plasmodium parasites to resist treatment. Almost all antimalarials are associated with parasite resistance, including the current first line treatment for Plasmodium falciparum malaria, the artemisinin combination therapies (ACTs), urging the need for new treatment and prevention options. Guidelines for new antimalarial drugs are continuously being revised, however, to address the issue of Plasmodium drug resistance, a novel mode of action is an important criterion. To address the need to identify novel drug targets for malaria, work in this thesis focused on an antiplasmodial natural product compound that appears to work differently to known malaria drugs. [...]